Lifeboat Foundation

A disclaimer on the new article that I wrote: while I do think the Beta-amyloid plaque plays a key role in the development of Alzheimer’s disease I do not think it’s the only thing. I’ll be writing more on Alzheimer’s disease as I study more.

The abnormal accumulation β-amyloid peptide is the leading candidate for the cause of Alzheimer’s disease is currently ranked the 6 th leading cause of death in the United States while some statistics claim it may rank as high as the third leading cause of death.

What is Alzheimer’s disease?

Continue reading “Deletion of BACE 1 Enzyme Reverses The Symptoms of Alzheimer’s” »

The abnormal accumulation β-amyloid peptide is the leading candidate for the cause of Alzheimer’s disease. Alzheimer’s disease is currently ranked the 6th leading cause of death in the United States while some statistics claim it may rank as high as the third leading cause of death.

What is Alzheimer’s disease?

Alzheimer’s is a slowly progressive disease that causes the loss of memories and cognitive function. It is the most common form of dementia and accounts for 60 to 80% of cases.

Continue reading “Deletion of BACE 1 Enzyme Reverses The Symptoms of Alzheimer's” »

An unusual transplant may revive tissues thought to be hopelessly damaged, including the heart and brain.

Cerebral small vessel disease (SVD) is one of the most commonly associated causes of age-related dementia and stroke. New research, led by the University of Edinburgh, may have finally uncovered the mechanism by which SVD causes brain cell damage, as well as a potential treatment to prevent the damage, and possibly even reverse it.

SVD is thought to be responsible for up to 45 percent of dementia cases, and the vast majority of senior citizens are suspected of displaying some sign of the condition. One study strikingly found up to 95 percent of subjects between the ages of 60 and 90 displayed some sign of SVD when examined through MRI scans.

The new research set out to examine early pathological features of SVD and found that dysfunction in endothelial cells are some of the first signs of the disease’s degenerative progression. These are cells that line small blood vessels in the brain and, in early stages of SVD, they secrete a protein that impairs production of myelin, a compound essential for the protection of brain cells.

Continue reading “New drug shows promise for preventing and even reversing damage from age-related dementia and stroke” »

European nations see biggest increases in use of stimulants such as Ritalin by people seeking brain-boosting effects.

• By Arran Frood, Nature magazine on July 6, 2018

Marvin Minsky was one of the founding fathers of artificial intelligence and co-founder of the Massachusetts Institute of Technology’s AI laboratory.

Abstract for scientists

Continue reading “Official Neurocluster Brain Model site” »

The workings of memory and learning have yet to be clarified, especially at the neural circuitry level. But researchers at Uppsala University have now, jointly with Brazilian collaborators, discovered a specific brain neuron with a central role in learning. This study, published in Neuron, may have a bearing on the potential for counteracting memory loss in Alzheimer’s disease.

When a person with dementia forgets having just eaten dinner, it is due to hippocampus damage. In contrast, the same person can describe in vivid detail a fishing trip to Norway 40 years ago. Both cases entail the use of episodic memory, the brain’s storage of events in which we have been personally involved. Dementia diseases impair the ability to form new memories, especially of events since the onset of the disease.

Researchers at Uppsala University have now, jointly with Brazilian colleagues, found certain neurons in the brain that play a crucial part in learning. The same research group had previously discovered ‘gatekeeper cells’ or, in technical parlance, OLM (Oriens-lacunosum moleculare) cells. These are located in the hippocampus, the brain area known to be active in forming new memories. The new findings from Klas Kullander’s research group show that OLM cells’ activity affects the encoding of memories in the brain.

Continue reading “Neuroscientists Improve Memory Formation, Provide Hope for Alzheimer’s Patients” »

https://paper.li/e-1437691924#/

They have been called the main news channel internationally and have a wider range than CNN and Al Jazeera. They have also taken the right to broadcast the best documentary on the development of mind control as a major political program. The Spanish TV-producer Daniel Estulin made the 25 minute presentation and interviewed Magnus Olsson who presented examples of victims that can be subjected to life-destructive research without their consent. The introduction gives a picture from the 1960s CIA project MKULTRA with tens of thousands of victims and a research based on state crime, medical abuse and kept beyond public attention.

University hospitals in the United States and Europe were central places where patients were implanted, utilized and misused for a life time of brain research and experiments. That situation has a similar pattern internationally and was built in behind the military and intelligence agencys classified operations. In Sweden the military research institution FOI became the innovator, knowledge bank and educated professors and physicians in collaboration with hospitals where the project was given highest priority.

Continue reading “Mind Control World CACH” »

An exciting experimental drug developed by scientists at Johns Hopkins Medicine has been found to stop the progression of Parkinson’s disease in live mice models. The new drug could be the first medication to specifically slow the progression of the devastating disease as opposed to current treatments that only target the symptoms.

Microglia are a kind of immune cell primarily found in the brain. One of the neurodegenerative processes that occurs in the brains of Parkinson’s disease patients is when the microglial cells send chemical signals to another kind of brain cell called astrocytes. This signal spurns those astrocytes into more aggressive behaviors, eating away at connections between neurons.

“The activated astrocytes we focused on go into a revolt against the brain,” explains Ted Dawson, one of the researchers on the project, “and this structural breakdown contributes to the dead zones of brain tissue found in those with Parkinson’s disease. The idea was that if we could find a way to calm those astrocytes, we might be able to slow the progression of Parkinson’s disease.”

Continue reading “Drug that stops progression of Parkinson’s disease heads for human trials” »